Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al

Ann Rheum Dis. 2018 Oct;77(10):e68. doi: 10.1136/annrheumdis-2017-212602. Epub 2017 Nov 13.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adalimumab
  • Antirheumatic Agents*
  • Arthritis, Rheumatoid*
  • Humans

Substances

  • Antirheumatic Agents
  • Adalimumab